Ply Gem Holdings, Inc., together with its subsidiaries, makes and sells residential and commercial building products primarily in the United States and Canada. The company has market cap of $1.48 billion. The firm operates in two divisions, Siding, Fencing and Stone; and Windows and Doors. It has a 21.74 P/E ratio. The Siding, Fencing and Stone segment offers vinyl siding and skirting, steel siding, vinyl and aluminum soffit, aluminum trim coils, cellular PVC trims and moldings, J-channels, wide crown moldings, window and door trims, F-channels, H-molds, fascia, undersill trims, outside/inside corner posts, rain removal systems, vinyl fences, vinyl railings, and stone veneer products, as well as injection molded designer accents, such as shakes, shingles, scallops, shutters, vents, and mounts.
The stock of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a huge mover today! The stock increased 0.66% or $0.34 during the last trading session, reaching $52.03. About 384,869 shares traded. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has risen 32.81% since March 19, 2017 and is uptrending. It has outperformed by 16.11% the S&P500.The move comes after 8 months positive chart setup for the $6.53 billion company. It was reported on Mar, 19 by Barchart.com. We have $54.11 PT which if reached, will make NASDAQ:IONS worth $261.00 million more.
Ratings analysis reveals 50% of Ply Gem Holdings’s analysts are positive. Out of 2 Wall Street analysts rating Ply Gem Holdings, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. PGEM was included in 2 notes of analysts from September 20, 2016. The firm earned “Sector Weight” rating on Tuesday, October 18 by KeyBanc Capital Markets. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, September 20.
Rutabaga Capital Management Llc Ma holds 3.51% of its portfolio in Ply Gem Holdings, Inc for 964,295 shares. Covalent Partners Llc owns 224,694 shares or 2.6% of their US portfolio. Moreover, New Generation Advisors Llc has 2.05% invested in the company for 194,607 shares. The Texas-based Hillcrest Asset Management Llc has invested 1.51% in the stock. Walthausen & Co. Llc, a New York-based fund reported 782,102 shares.
Analysts await Ply Gem Holdings, Inc (NYSE:PGEM) to report earnings on May, 14. They expect $0.08 earnings per share, up 300.00% or $0.12 from last year’s $-0.04 per share. PGEM’s profit will be $5.49 million for 67.27 P/E if the $0.08 EPS becomes a reality. After $0.16 actual earnings per share reported by Ply Gem Holdings, Inc for the previous quarter, Wall Street now forecasts -50.00% negative EPS growth.
The stock decreased 0.12% or $0.025 during the last trading session, reaching $21.525. About 166,135 shares traded. Ply Gem Holdings, Inc (PGEM) has risen 22.22% since March 19, 2017 and is uptrending. It has outperformed by 5.52% the S&P500.
Analysts await Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to report earnings on May, 8. They expect $-0.11 earnings per share, down 466.67% or $0.14 from last year’s $0.03 per share. After $0.02 actual earnings per share reported by Ionis Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -650.00% negative EPS growth.
Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company has market cap of $6.53 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. It currently has negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis.